文献类型：期刊文献

英文题名：Levels of effectiveness of gene therapies targeting survivin and its splice variants in human breast cancer cells

作者：Zheng, Wenyun[1];Kang, Yanyan[2];Li, Linfeng[2];Xu, Yuxin[2];Ma, Xingyuan[2]

机构：[1]East China Univ Sci & Technol, Sch Pharm, State Key Lab Bioreactor Engn, Shanghai, Peoples R China;[2]East China Univ Sci & Technol, Sch Biotechnol, State Key Lab Bioreactor Engn, Shanghai 200237, Peoples R China

年份：2011

卷号：5

期号：6

起止页码：293

外文期刊名：DRUG DISCOVERIES AND THERAPEUTICS

收录：WOS:【ESCI(收录号:WOS:000214933300005)】；

基金：This work was supported by China's National Natural Science Foundation (30873190), the National Science Research Project "Significant New Drugs Created" of the Eleventh Five-year Plan (2009ZX09103-693), the Fundamental Research Funds for the Central Universities from the Ministry of Education (WK0913002), and the Open Funding Project of the State Key Laboratory of Bioreactor Engineering.

语种：英文

外文关键词：Survivin; splice variant; growth inhibition; apoptosis; breast cancer

摘要：In order to develop an effective strategy of breast cancer therapy targeting survivin and its splice variants survivin-Delta Ex3 and survivin-2B, the present study constructed four expression vectors by fusing the survivin antisense gene, the survivin (T34A) gene, the survivin-Delta Ex3 antisense gene, and the survivin-2B gene with the enhanced green fluorescent protein (eGFP) gene. Each of these vectors was transiently transfected into the B-Cap-37 human breast cancer cell line. The effects of these four vectors with diverse genes on the proliferation and apoptosis of B-Cap-37 breast cancer cells were examined and compared in vitro using MTT and flow cytometry assays. Results of the MTT assay indicated that all four gene therapy plasmids were most effective at inhibiting the proliferation of B-Cap-37 cells 72 h after transfection. However, the four gene therapies had different rates of cell inhibition. pcDNA3.1(+)-egfp-anti-survivin and pcDNA3.1(+)-survivin (T34A)-egfp had almost equivalent or better effectiveness at suppressing cell growth. pcDNA3.1(+)-egfp-anti-survivin-Delta Ex3 moderately inhibited the growth of B-Cap-37 cells. In contrast, pcDNA3.1(+)-survivin-2B-egfp had limited inhibition of cell growth. Similar profile of effectiveness of four gene therapies in soliciting cell apoptosis was also observed. These results suggest the relative importance of targeting survivin and its splice variant survivin-Delta Ex3 in breast cancer treatment.